Chronic Levodopa Administration Followed by a Washout Period Increased Number and Induced Phenotypic Changes in Striatal Dopaminergic Cells in MPTP-Monkeys
In addition to the medium spiny neurons the mammalian striatum contains a small population of GABAergic interneurons that are immunoreactive for tyrosine hydroxylase (TH), which dramatically increases after lesions to the nigrostriatal pathway and striatal delivery of neurotrophic factors. The regulatory effect of levodopa (L-Dopa) on the number and phenotype of these cells is less well understood. Eleven macaques (Macaca fascicularis) were included. Group I (n = 4) received 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) and L-Dopa; Group II (n = 4) was treated with MPTP plus vehicle and Group III (n = 3) consist of intact animals (control group). L-Dopa and vehicle were given for 1 year and animals sacrificed 6 months later. Immunohistochemistry against TH was used to identify striatal and nigral dopaminergic cells. Double and triple labeling immunofluorescence was performed to detect the neurochemical characteristics of the striatal TH-ir cells using antibodies against: TH, anti-glutamate decarboxylase (GAD67) anti-calretinin (CR) anti-dopa decarboxylase (DDC) and anti-dopamine and cyclic AMP-regulated phosphoprotein (DARPP-32). The greatest density of TH-ir striatal cells was detected in the striatum of the L-Dopa treated monkeys and particularly in its associative territory. None of the striatal TH-ir cell expressed DARPP-32 indicating they are interneurons. The percentages of TH-ir cells that expressed GAD67 and DDC was approximately 50%. Interestingly, we found that in the L-Dopa group the number of TH/CR expressing cells was significantly reduced. We conclude that chronic L-Dopa administration produced a long-lasting increase in the number of TH-ir cells, even after a washout period of 6 months. L-Dopa also modified the phenotype of these cells with a significant reduction of the TH/CR phenotype in favor of an increased number of TH/GAD cells that do not express CR. We suggest that the increased number of striatal TH-ir cells might be involved in the development of aberrant striatal circuits and the appearance of L-Dopa induced dyskinesias.
References
[1]
Graveland GA, DiFiglia M (1985) The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum. Brain Res 327: 307–11.
[2]
DiFiglia M, Pasik P, Pasik T (1976) A golgi study of neuronal types in the neostriatum of monkeys. Brain Res 114: 245–56.
[3]
Bishop GA, Chang HT, Kitai ST (1982) Morphological and physiological properties of neostriatal neurons: An intracellular horseradish peroxidase study in the rat. Neuroscience 7: 179–91.
[4]
Tashiro Y, Sugimoto T, Hattori T, Uemura Y, Nagatsu I, et al. (1989) Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat. Neurosci Lett 97: 6–10.
[5]
Mura A, Jackson D, Manley MS, Young SJ, Groves PM (1995) Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: A possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res 704: 51–60.
[6]
Meredith GE, Farrell T, Kellaghan P, Tan Y, Zahm DS, et al. (1999) Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions. Eur J Neurosci 11: 3585–96.
[7]
Dubach M, Schmidt R, Kunkel D, Bowden DM, Martin R, et al. (1987) Primate neostriatal neurons containing tyrosine hydroxylase: Immunohistochemical evidence. Neurosci Lett 75: 205–10.
[8]
Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, et al. (1997) Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 17: 6761–8.
[9]
Mazloom M, Smith Y (2006) Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri？dine-treatedmonkeys. J Comp Neurol 495: 453–69.
[10]
Tande D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, et al. (2006) New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 129: 1194–200.
[11]
Huot P, Levesque M, Parent A (2007) The fate of striatal dopaminergic neurons in parkinson's disease and huntington's chorea. Brain 130: 222–32.
[12]
Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, et al. (2000) New dopaminergic neurons in parkinson's disease striatum. Lancet 356: 44–5.
[13]
Cossette M, Lecomte F, Parent A (2005) Morphology and distribution of dopaminergic neurons intrinsic to the human striatum. J Chem Neuroanat 29: 1–11.
[14]
Cossette M, Parent A, Levesque D (2004) Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. The European Journal of Neuroscience 20: 2089–2095.
[15]
Ibanez-Sandoval O, Tecuapetla F, Unal B, Shah F, Koos T, et al. (2010) Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J Neurosci 30: 6999–7016.
[16]
Bezard E, Gross CE (1998) Compensatory mechanisms in experimental and human parkinsonism: Towards a dynamic approach. Prog Neurobiol 55: 93–116.
[17]
Huot P, Levesque M, Morissette M, Calon F, Dridi M, et al. (2008) L-dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. J Chem Neuroanat 35: 77–84.
[18]
Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with huntington's disease. Brain Research.Brain Research Reviews 34: 80–101.
[19]
Luquin MR, Montoro RJ, Guillen J, Saldise L, Insausti R, et al. (1999) Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 22: 743–50.
[20]
Martin RF, Bowden DM (1996) A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. Neuroimage 4: 119–50.
[21]
San Sebastian W, Guillen J, Manrique M, Belzunegui S, Ciordia E, et al. (2007) Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft. Brain 130: 1306–16.
[22]
Bink K, Walch A, Feuchtinger A, Eisenmann H, Hutzler P, et al. (2001) TO-PRO-3 is an optimal fluorescent dye for nuclear counterstaining in dual-colour FISH on paraffin sections. Histochemistry and Cell Biology 115: 293–299.
[23]
Ouimet CC, Greengard P (1990) Distribution of DARPP-32 in the basal ganglia: An electron microscopic study. Journal of Neurocytology 19: 39–52.
[24]
Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, et al. (2002) Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 22: 4942–4954.
[25]
Brotchie J, Fitzer-Attas C (2009) Mechanisms compensating for dopamine loss in early parkinson disease. Neurology 72: S32–8.
[26]
Riverol M, Ordonez C, Marcilla I, DiCaudo C, Hernandez B, et al. (2011) Effect of MPTP and chronic levodopa treatment on striatal dopaminergic markers. Movement Disorders : Official Journal of the Movement Disorder Society 26: S25.
[27]
O'Sullivan SS, Johnson M, Williams DR, Revesz T, Holton JL, et al. (2011) The effect of drug treatment on neurogenesis in parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society 26: 45–50.
[28]
Jollivet C, Montero-Menei CN, Venier-Julienne MC, Sapin A, Benoit JP, et al. (2004) Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats. Neurosci Lett 362: 79–82.
[29]
Luquin MR, Manrique M, Guillen J, Arbizu J, Ordonez C, et al. (2011) Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates. Brain Res 1375: 120–7.
[30]
Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, et al. (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between parkinson's disease and nonhuman primate brains. Movement Disorders : Official Journal of the Movement Disorder Society 26: 27–36.
[31]
Hou JG, Lin LF, Mytilineou C (1996) Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. Journal of Neurochemistry 66: 74–82.
[32]
Bjugstad KB, Redmond DE, Teng YD, Elsworth JD, Roth RH, et al. (2005) Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: A return to control measures. Cell Transplantation 14: 183–192.
[33]
Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I (1992) Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Letters 313: 138–142.
[34]
Kay JN, Blum M (2000) Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Developmental Neuroscience 22: 56–67.
[35]
Luzzati F, De Marchis S, Parlato R, Gribaudo S, Schutz G, et al. (2011) New striatal neurons in a mouse model of progressive striatal degeneration are generated in both the subventricular zone and the striatal parenchyma. PloS One 6: e25088.
[36]
Haber SN (2003) The primate basal ganglia: Parallel and integrative networks. J Chem Neuroanat 26: 317–30.
[37]
Bernacer J, Prensa L, Gimenez-Amaya JM (2012) Distribution of GABAergic interneurons and dopaminergic cells in the functional territories of the human striatum. PloS One 7: e30504.
[38]
Calabresi P, Di Filippo M, Ghiglieri V, Picconi B (2008) Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23 Suppl 3S570–9.
[39]
Belujon P, Lodge DJ, Grace AA (2010) Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Movement Disorders : Official Journal of the Movement Disorder Society 25: 1568–1576.
[40]
Weihe E, Depboylu C, Schutz B, Schafer MK, Eiden LE (2006) Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell Mol Neurobiol 26: 659–78.
[41]
Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, et al.. (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of parkinson's disease. Neurobiol Dis.
